JCI The Journal of Clinical Investigation


Doxycycline host-directed therapy in human pulmonary tuberculosis

Qing Hao Miow, ..., Jon S. Friedland, Catherine W.M. Ong

J Clin Invest. 2021. https://doi.org/10.1172/JCI141895.

Clinical Medicine In-Press Preview Clinical trials Infectious disease

Graphical abstract



Find the latest version:



https://jci.me/141895/pdf

Title: 1

Doxycycline host-directed therapy in human pulmonary tuberculosis 2

3

4 **Authors:**

Qing Hao Miow¹, Andres F. Vallejo², Yu Wang¹, Jia Mei Hong¹, Chen Bai¹, Felicia S.W. Teo³, 5 Alvin D.Y. Wang⁴, Hong Rong Loh¹, Tuan Zea Tan⁵, Ying Ding⁶, Hoi Wah She⁷, Suay Hong 6

Gan⁷, Nicholas I. Paton¹, Josephine Lum⁸, Alicia Tay⁸, Cynthia B.E. Chee⁷, Paul A. Tambyah¹, 7

- Marta E. Polak^{2,9}, Yee Tang Wang⁷, Amit Singhal⁸, Paul T. Elkington¹⁰*, Jon S. Friedland¹¹, 8 Catherine W.M. Ong^{1,12}*
- 10

9

Affiliations: 11

- ¹ Infectious Diseases Translational Research Programme, Department of Medicine, Yong Loo 12
- Lin School of Medicine, National University of Singapore, 119228 Singapore, Singapore. 13
- ² Clinical and Experimental Sciences, Sir Henry Wellcome Laboratories, Faculty of Medicine, 14

15 University of Southampton, SO16 6YD Southampton, UK.

- ³ Division of Respiratory and Critical Care Medicine, University Medicine Cluster, National 16
- University Hospital, National University Health System, 119228 Singapore, Singapore. 17
- ⁴ Department of Medicine, Ng Teng Fong General Hospital, 609606 Singapore, Singapore. 18
- ⁵ Cancer Science Institute of Singapore, National University of Singapore, 117599 Singapore, 19
- Singapore. 20

1	⁶ National Centre for Infectious Diseases, 308442 Singapore, Singapore.
2	⁷ Tuberculosis Control Unit, Tan Tock Seng Hospital, 308089 Singapore, Singapore.
3	⁸ Singapore Immunology Network, A*STAR, 138648 Singapore, Singapore.
4	⁹ Institute for Life Sciences, University of Southampton, SO17 1BJ Southampton, UK.
5	¹⁰ NIHR Respiratory Biomedical Research Centre, Faculty of Medicine, University of
6	Southampton, SO16 6YD Southampton, UK.
7	¹¹ St George's, University of London, SW17 0RE London, UK.
8	¹² Institute for Health Innovation & Technology, National University of Singapore, 117599
9	Singapore, Singapore.
10	
11	*Co-corresponding authors:
12	Catherine W.M. Ong, NUHS Tower Block level 10, 1E Kent Ridge Road, 119228
13	Singapore, Singapore, phone: +65 6772 7854, email: Catherine.ong@nus.edu.sg
14	
15	Paul T. Elkington, LE75, South Academic Block, Southampton General Hospital, SO16
16	6YD Southampton, UK, phone: +44 23 8120 5928, email: p.elkington@soton.ac.uk
17	
18	The authors have declared that no conflict of interest exists.
19	
20	The funding sources had no role in the design, execution, analyses and data interpretation
21	of this study, and the decision to submit results for publication.

1 Abstract (247 / 250 word limit)


BACKGROUND. Matrix metalloproteinases (MMPs) are implicated as key regulators of tissue
destruction in tuberculosis (TB) and may be a target for host-directed therapy. Here, we conducted
a Phase 2 randomized, double-blind, placebo-controlled trial investigating doxycycline, a licensed
broad spectrum MMP inhibitor, in pulmonary TB patients.

METHODS. Thirty pulmonary TB patients were enrolled within 7 days of initiating anti-TB
treatment and randomly assigned to receive either doxycycline 100 mg or placebo twice a day for
14 days in addition to standard care.

9 **RESULTS.** There were significant changes in the host transcriptome, and suppression of systemic and respiratory markers of tissue destruction with the doxycycline intervention. Whole blood 10 11 RNA-sequencing demonstrated that doxycycline accelerated restoration of dysregulated gene 12 expression patterns in TB towards normality, with more rapid down-regulation of type I and II interferon and innate immune response genes and concurrent up-regulation of B-cell modules 13 relative to placebo. The effects persisted for 6 weeks after doxycycline was discontinued, 14 15 concurrent with suppression of plasma MMP-1. In respiratory samples, doxycycline reduced MMP-1, -8, -9, -12 and -13 concentrations, suppressed type I collagen and elastin destruction, and 16 reduced pulmonary cavity volume despite unchanged sputum Mycobacterium tuberculosis loads 17 between the study arms. Two weeks of adjunctive doxycycline with standard anti-TB treatment 18 was well-tolerated, with no serious adverse events related to doxycycline. 19

20 **CONCLUSION.** These data demonstrate that adjunctive doxycycline with standard anti-TB 21 treatment suppresses pathological MMPs in pulmonary tuberculosis patients, and suggest that 22 larger studies on adjunctive doxycycline to limit immunopathology in TB are merited.

1 **GRAPHICAL ABSTRACT.**



3 **TRIAL REGISTRATION.** ClinicalTrials.gov, NCT02774993.

4

2

FUNDING. Singapore National Medical Research Council (NMRC/CNIG/1120/2014, 5 NMRC/Seedfunding/0010/2014 and NMRC/CISSP/2015/009a), Singapore Infectious Diseases 6 7 Initiative (SIDI/2013/013), National University Health System Singapore (PFFR - 28 January 14 and NUHSRO/2014/039/BSL3-SeedFunding/Jul/01) and Immunomonitoring platform grant to 8 SIgN (BMRC/IAF/311006, H16/99/b0/011 and NRF2017_SISFP09). C.W.M.O. was also funded 9 by the NUS ExxonMobil Research Fellowship, the NUHS Clinician Scientist Program, 10 NMRC/TA/0042/2015 and CSAINV17nov014. P.T.E. was supported by the UK Medical 11 Research Council (MR/P023754/1 and MR/N006631/1). Q.H.M. was supported by the NUS 12

Medicine Post-doctoral Fellowship. A.F.V. was supported by The Royal Society Challenge Grant
 (CHG\R1\170084). M.E.P. was funded by Sir Henry Dale Fellowship, Wellcome Trust
 (109377/Z/15/Z). A.S. is supported by A*STAR.

1 Introduction

Globally, an estimated 10 million people develop tuberculosis (TB) each year and TB 2 remains the leading cause of death from a single infectious agent (1). Standard short-course anti-3 4 TB treatment still requires antimicrobial drugs of at least 6 months, and drug-resistant TB is an increasing public health threat. Even after microbiological cure of TB, patients often suffer from 5 significant sequelae, such as residual or secondary lung diseases (2). A recent meta-analysis 6 7 revealed that TB survivors have approximately 3 to 4 times greater mortality than their local 8 population (3). Consequently, there is interest in adjunctive host-directed therapies that may modulate host immune responses to Mycobacterium tuberculosis (Mtb) to improve the efficacy of 9 10 anti-TB drugs, shorten treatment duration, and limit associated tissue damage (4-12). These aims are unlikely to be met by antimicrobial treatment alone. 11

12 *Mtb* causes apical pulmonary disease in the immunocompetent host and drives destructive 13 pathology resulting in pulmonary cavity formation (13-15). Cavities are sites of high 14 mycobacterial burden, and are poorly penetrated by anti-TB drugs, leading to the persistence of drug-tolerant bacilli and contribute to the transmission of infectious bacilli (16-18). After 15 completion of anti-TB treatment, the sequelae of tissue damage include permanent respiratory 16 17 dysfunction in the form of pulmonary fibrosis or post-TB bronchiectasis, which can lead to decreased effort tolerance, infectious exacerbations resulting in repeated hospitalizations and 18 reduced quality of life (6, 19-21). Furthermore, several population-based studies have 19 demonstrated that a history of treated TB increases the risk of obstructive airway disease, 20 independent of smoking and other clinical factors (22-24). 21

Pathological destruction of the highly stable network of collagen fibrils in the lung
 parenchyma is mainly mediated by proteases, in particular, MMPs (10, 15, 17, 18, 25, 26). MMPs

are a family of zinc-dependent proteases that may collectively degrade all fibrillar components of 1 the extracellular matrix at neutral pH and are involved in diverse physiological processes, 2 3 including tissue modeling, organ development and regulation of immune responses (27, 28). MMP concentrations [MMP-1, -2, -3, -7, -8, -9, and -10] and their matrix degradation products, 4 procollagen III N-terminal propeptide (PIIINP) and desmosine, are consistently found to be 5 6 elevated in respiratory samples from pulmonary TB patients compared to patients with other respiratory diseases and healthy volunteers (29-32). Increased MMP concentrations associate with 7 markers of pulmonary TB disease severity, such as sputum smear status, radiographic disease 8 9 extent and presence of cavitation (29, 33). In addition, Mtb infection and/or stimulation by conditioned media from Mtb-infected monocytes induced secretion of MMPs with proteolytic 10 activity in cellular models of human bronchial epithelial cells, monocyte-derived macrophages and 11 neutrophils (14, 34-38), as well as in animal models (26, 39). These observations implicate MMPs 12 as dominant effectors of lung matrix destruction in pulmonary TB and consequently MMPs are 13 14 attractive host targets for adjunctive host-directed therapies.

Currently, the only licensed MMP inhibitor is doxycycline, a tetracycline antibiotic with 15 broad spectrum MMP inhibitory activity (40). Doxycycline suppresses Mtb-induced MMP 16 17 secretion in cellular models (29) and limits collagen destruction by *Mtb*-induced MMPs (14, 31). 18 Doxycycline treatment inhibits MMP activity in periodontal disease at 20 mg twice daily (41) and 19 improves lung function in inflammatory lung disorders, such as chronic obstructive pulmonary disease (COPD) (42) and asthma (43). In a guinea pig model of TB, doxycycline monotherapy 20 21 reduced the lung mycobacterial burden in a dose-dependent manner (29), and in the mouse model 22 of TB, MMP inhibition improved drug efficacy (39). However, adjunctive doxycycline treatment in TB patients has not been evaluated. 23

Here, we performed a first-in-human pilot Phase 2 randomized, double-blind, placebocontrolled trial to investigate the effects of doxycycline on the host transcriptome, mycobacterial burden and biological markers of tissue destruction, including pulmonary cavitation, as well as concentrations of MMPs, tissue inhibitor of metalloproteinases (TIMPs) and matrix degradation products in patients with drug-susceptible pulmonary TB. Concurrently, we assessed the safety of adjunctive doxycycline treatment with standard anti-TB therapy.

1 Results

2 *Study profile and safety analyses.*

3 A total of 143 pulmonary TB patients who were HIV negative were pre-screened, of which 33 were assessed for eligibility. 30 pulmonary TB patients were enrolled within 7 days of initiating 4 anti-TB treatment and randomly assigned to either doxycycline or placebo (Figure 1). The baseline 5 6 clinical, laboratory and radiologic characteristics at enrolment were similar between the study arms (Table 1). Six (20%) of the 30 TB patients were female and nine (30%) had diabetes mellitus with 7 8 a mean HbA1c of 11.3%. The median chest X-ray (CXR) score was 2.8 (IQR 1.9 – 4.6) and 19 9 (63%) patients had pulmonary cavities. Two patients had isoniazid mono-resistant Mtb while the remaining 28 had fully drug-sensitive Mtb. 10

11 In the doxycycline arm, two patients withdrew due to adverse events (both Grade 1 nausea and vomiting), while in the placebo arm, one patient developed neutropenia and was withdrawn 12 by the managing physician, and one by the investigator's decision as the patient was found to have 13 cognitive impairment after randomization. Thus, there were 13 patients in each arm, who 14 15 completed the allocated intervention (took at least 24 out of the 28 doses of the study drug), and were followed up for 2 months (Figure 1). Subsequently, one patient in the placebo arm declined 16 phlebotomy at Day 14, and another patient's neutrophil and monocyte samples in the doxycycline 17 arm was not processed due to electrical failure at the laboratory, which led to analysis of 12 blood 18 samples in each arm. 19

Among all the 30 enrolled patients, there was no difference between the study arms due to any adverse events (relative risk [RR] 1.1, 95% CI 0.69 - 1.76, Supplemental Table 1), or presumed toxic effects (any grade 3 or 4 events, or serious adverse events). Patients in the doxycycline arm tended to experience more nausea and vomiting (RR 3.0, 95% CI 0.72 - 12.56) and rash (RR 3.0, 95% CI 0.35 – 25.69), but there was no statistical significance between the arms
(*p*-value = 0.21 and *p*-value = 0.60 by Fisher's exact test, respectively, Supplemental Table 1).
One patient in the doxycycline arm developed Grade 4 neutropenia attributed to anti-TB treatment
which persisted after completion of the intervention. Two patients in the placebo arm developed
serious adverse events: one had prolonged hospitalization due to paradoxical reaction and another
developed dyspnea requiring a visit to the Emergency Department that resolved.

Ten healthy volunteers (5 males and 5 females) were also enrolled and received doxycycline 100 mg twice a day for 14 days. All 10 volunteers completed at least 24 out of the 28 doses of doxycycline and were followed for 2 months. No subject discontinued participation in the study due to a doxycycline-related adverse event and no serious adverse events were observed (Supplemental Table 2). Two out of ten volunteers developed Grade 1 nausea and vomiting which resolved on completion of the drug course (Supplemental Table 2).

13

14 *Clinical, radiological and microbiological outcomes were similar between study arms.*

There were no difference in median BMI, and chest X-ray (CXR) score between doxycycline and placebo-treated patients at any time point (Table 1). Although doxycycline is bacteriostatic to *Mtb in vitro* (29, 44, 45), sputum *Mtb* burden was unchanged between the study arms. Two patients in the placebo arm and one in the doxycycline arm had positive sputum *Mtb* cultures at 2 months into anti-TB treatment (Table 1, *p*-value = 1.00). Pulmonary cavities resolved in 4 out of seven patients (57%) in the doxycycline arm compared to 2 out of nine (22%) in the placebo arm by the end of 2 months, but this finding was not statistically significant.

1 Gene expression of MMPs and immuno-regulatory genes are dysregulated in patients with TB.

To analyze the effects of *Mtb* infection and doxycycline in an unbiased manner, we first 2 studied baseline differences between blood transcriptomes of TB patients and healthy volunteers. 3 4 After normalization and filtering, principal component analysis (PCA) showed differentiation between healthy volunteers and TB patients, although with significant inter-individual variation, 5 as expected from human disease with diverse severity (Supplemental Figure 1A). Differential 6 7 gene expression (DEG) analysis using generalized linear models (EdgeR) (46) identified 1657 8 DEGs, including 853 genes up-regulated in TB patients. As evaluated by gene ontology analyses, these genes mostly encoded for immune response and detection of bacterial molecules 9 10 (Supplemental Figure 1B), while pathway enrichment identified immune, infectious and inflammatory pathways (Supplemental Figure 1C). To visualize the extent of changes induced by 11 *Mtb* infection in the blood cell transcriptome, significantly regulated genes were plotted onto the 12 diagrams of individual KEGG pathways (47-49), including the TB pathway (Supplemental Figure 13 14 2) and the TNF signalling pathway (Supplemental Figure 3), which demonstrated extensive changes in gene expression in each pathway. 15

16 Co-expression module analysis using CEMITool (50) identified 3 modules (module 1, 2 and 4) to be differentially enriched in TB patients compared with healthy volunteers (Supplemental 17 Figure 4A). Modules 2 and 4 were specifically overexpressed in TB, with normalized enrichment 18 scores of 1.96 and 1.45, respectively. Module 2 was predominantly enriched for immune 19 20 activation, neutrophils, extracellular matrix and dendritic cells, all of which have been described to be important pathways in TB (Supplemental Figure 4B). Module 4 was dominated by B cell 21 signatures, which are being recognized as of increasing importance in the host immune response 22 to TB (Supplemental Figure 4C). Of note, expression of matrix metalloproteinases was increased 23

in module 2, including *MMP8* and *MMP9*, as well as *PLAUR*, encoding a receptor for urokinase
plasminogen activator involved in extracellular matrix degradation (Supplemental Figure 4D). In
module 4, genes were involved in immuno-regulation, including *IFIT3*, *MX2* and *TNFAIP6*(Supplemental Figure 4E). Quantitative PCR (qPCR) validated up-regulation of these genes in
TB (Supplemental Figures 4F and G).

6

Doxycycline modulates diverse host immune pathways, with effects persisting 6 weeks after
doxycycline discontinuation.

9 Next, we investigated the effect of doxycycline therapy over time on the blood 10 transcriptome. There was significant donor-to-donor variability, consistent with studying human 11 disease. In PCA analysis, the inter-individual differences were reduced between Day 0 and Day 12 14 as analyzed in the doxycycline arm (Figure 2A), but in the placebo arm, greater dispersal 13 between patients occurred between Day 0 and Day 14 (Figure 2B).

To investigate this phenomenon further, we performed paired analysis in each study arm 14 to identify genes that were differentially expressed over time. Doxycycline led to a more rapid 15 16 normalization of immune response genes towards expression levels in healthy volunteers, such as SLC26A8, IGSF6, PYGL, GBP6 and CLEC12B (Supplemental Figures 5A-E). Similarly, in a 17 parallel unbiased co-expression network analysis using GraphiaPro (51), 27 co-expressed clusters 18 19 were identified (Figure 2C; Supplemental Table 3). These clusters comprised genes highly expressed in TB that were down-regulated during the course of treatment with doxycycline but 20 were up-regulated or unaltered in the placebo arm (Figures 2D-I). Of note, one cluster encoded 21 type I interferon signalling pathway (adjusted *p*-value = 5.20×10^{-19}), while another cluster encoded 22 cellular response to interferon-gamma (adjusted p-value = 5.05×10^{-14}) and innate immune 23

responses (adjusted *p*-value = 2.17×10^{-12}). In addition, the latter cluster comprised *IRF1*, *APOL1*, *FCGR1A*, *FCGR1B*, *GBP5*, and *GBP6*, genes all related to the innate immune response, indicating doxycycline selectively modulates innate immunity (Figures 2D-I). Furthermore, although doxycycline was only administered for the first 14 days of treatment, the effects on gene expression were still observed at Day 56. Similar observations were found in the qPCR validation of these genes (Supplemental Figures 5F-K).

7 To further assess the effect of doxycycline on specific signalling pathways in comparison 8 with placebo, we performed Ensemble of Gene Set Enrichment Analyses (EGSEA) (52), combining results from eleven algorithms to calculate collective gene set scores for biological 9 10 relevance of the highest ranked gene sets. Mapping of the divergently regulated genes onto the KEGG TB pathway (EGSEA adjusted p-value = 0.0047 for doxycycline treatment) visualized that 11 doxycycline modulated numerous different stages of the pathway, with expression changes often 12 in the opposite direction to placebo (Figure 3). A parallel analysis of biological processes and 13 14 pathway enrichment in genes differentially regulated between Day 14 and Day 0 in doxycycline and placebo arms across all available Gene Ontology and Hallmark signatures demonstrated 15 multiple pathways divergently regulated by doxycycline (Supplemental Figures 6A and B). 16

To further dissect which pathways were significantly changed in the doxycycline arm but not placebo, a comparison within linear model was used for identification of doxycycline-specific DEGs (EdgeR, contrasts: (Doxy_Day14-Doxy_Day0)-(Placebo_Day14-Placebo_Day0)). Gene Set Enrichment Analysis using Camera (53) with blood transcriptional modules (54) showed that several pathways were more significantly regulated in the doxycycline arm than the placebo arm (Figure 4A; Supplemental Figure 6C), including interferon responses (Figure 4B), T cell responses and innate responses. In addition, B cell responses increased with doxycycline treatment (Figure 4A). Finally, we studied gene expression of extracellular matrix related genes and showed a trend towards reduction with doxycycline (Figure 4C). Within this pathway, doxycycline led to a significant reduction of *MMP9* gene expression compared to placebo (Figure 4D; adjusted pvalues = 1.00 and 0.003 for placebo and doxycycline arms, respectively).

5

6 Systemic MMPs are inhibited by doxycycline

7 Since the unbiased blood transcriptomic analysis identified up-regulated extracellular 8 matrix-related genes in TB, and doxycycline suppressed MMP9 expression, we next investigated 9 the effect of adjunctive doxycycline on plasma MMPs. Plasma MMP-1 was significantly 10 suppressed at Day 56 by doxycycline (Figure 5A, adjusted *p*-value < 0.05). A similar trend was 11 observed for plasma MMP-8 (Figure 5B, adjusted p-value = 0.06 at Day 56). These data show 12 that systemic MMP-1 continues to be suppressed at a protein level at a late time point, even after doxycycline treatment was stopped after 14 days, consistent with the observations in the blood 13 transcriptomic analysis (Figures 2D-I). Fold change of the tissue inhibitor of MMPs, TIMP-1 and 14 15 -2, in the plasma were not different between both arms (Figures 5C and D). Other plasma MMPs were unchanged between arms (Supplemental Figures 7A-F). 16

Next, we analyzed the fold change of circulating matrix degradation products of Type III collagen, PIIINP (32) and desmosine from elastin fibers (55). Both were unchanged in TB patients' plasma (Supplemental Figures 7G and H). In addition, *Mtb*-induced MMP secretion from *ex vivo* culture of neutrophils (Supplemental Figures 8A and B) and monocytes (Supplemental Figures 9A-G) were not different between doxycycline and placebo-treated TB patients.

- Doxycycline suppresses MMPs in respiratory secretions and decreases extracellular matrix
 degradation with a concurrent decrease in pulmonary cavity volume
- 2

Since MMP activity is tightly regulated and may be compartmentalized (56), we next 3 investigated MMPs in respiratory samples to determine the effect of doxycycline in the lung. 4 Sputum MMP-1, -8, -9, -12 and -13 fold changes were significantly decreased by doxycycline 5 relative to placebo (Figures 6A-C; Supplemental Figures 10A and B), while other MMPs were 6 7 unchanged (Supplemental Figures 10C-G). From Day 0 to Day 14, collagenases MMP-1, -8 and gelatinase MMP-9 were decreased in the doxycycline arm (mean fold change of Day 14 vs. Day 0 8 \pm s.e.m.; MMP-1: 0.45 \pm 0.16, MMP-8: 0.38 \pm 0.10, MMP-9: 0.45 \pm 0.10), while in the placebo 9 10 arm, they remained unchanged or increased (mean fold change of Day 14 vs. Day $0 \pm$ s.e.m.; MMP-1: 1.46 ± 0.50 , MMP-8: 1.62 ± 0.62 , MMP-9: 2.19 ± 0.90). Inhibitors TIMP-1 and -2 were 11 not significantly different between the two arms (Figures 6D and E), indicating an overall 12 suppression of sputum MMP activity by doxycycline. 13

14 Next, we examined the effects of doxycycline on sputum enzymatic activity degrading Type I collagen and elastin, which are key lung extracellular matrix proteins (57, 58). Type I 15 collagen is the substrate of MMP-1 and -8, while elastin is a substrate of MMP-9 (59). In 16 17 doxycycline-treated TB patients, sputum Type I collagenase and elastase activities were significantly decreased compared to placebo-treated patients (Figures 6F and G), consistent with 18 the observed decrease in sputum MMP-1, -8 and -9 concentrations (Figures 6A-C). Furthermore, 19 20 a decrease in pulmonary cavity volume was observed in the doxycycline arm at Day 56, while no difference was observed in the placebo arm (Figure 6H; adjusted p-value = 0.045). Total sputum 21 PIIINP fold change was unchanged between the two arms (Supplemental Figure 10H), while 22

- 1 sputum desmosine showed a non-significant trend towards suppression in the doxycycline arm
- 2 (Supplemental Figure 10I; adjusted p-value = 0.06).

1 Discussion

Our phase II randomized controlled trial is an exploratory study to investigate the effects 2 of adjunctive doxycycline to standard anti-TB treatment in 30 pulmonary TB patients. 3 4 Doxycycline significantly regulated the host transcriptome and biological markers of tissue 5 destruction. We demonstrate for the first time in TB patients that adjunctive treatment with doxycycline regulated expression of immune and inflammatory response genes, and these effects 6 7 persisted for six weeks after completion of two weeks doxycycline intervention. Pathway analyses 8 revealed that doxycycline down-regulated type I/II interferon and innate immune response genes and up-regulated genes involved in B-cell biology. Gene expression of the extracellular matrix-9 10 related gene set showed a trend towards reduction in the doxycycline arm, with significant MMP-11 9 gene suppression. At the protein level, doxycycline suppressed systemic MMP-1, while in the respiratory compartment, collagenases MMP-1 and -8 and gelatinase MMP-9 were reduced. 12 Doxycycline reduced total functional Type 1 collagenase and elastase activities in TB patients' 13 14 sputum with a concurrent significant decrease in pulmonary cavity volume. There was no change in BMI which is reassuring as a low BMI is associated with mortality (60). Our findings in TB 15 16 patients extend previous in vitro observations that doxycycline inhibits MMP activity in cellular 17 TB models (14, 29) and suggest that MMP inhibition may be associated with decreased tissue damage in TB. Finally, we show that adjunctive doxycycline with standard anti-TB treatment was 18 19 safe.

Whole blood RNA-sequencing dissected the molecular pathways affected by adjunctive doxycycline in pulmonary TB patients. Using co-expression network analysis, we found immune response genes, such as *IRF1*, *APOL1*, *FCGR1A*, *FCGR1B*, *GBP5* and *GBP6* to be specifically down-regulated by doxycycline treatment towards the expression levels in healthy volunteers. Of

note, these genes are often elevated in TB patients and have been repeatedly identified in blood
gene signatures proposed to diagnose TB with high sensitivity and specificity (61-64).

Co-expression network analysis revealed that doxycycline led to greater down-regulation 3 4 of type I/II interferon and innate immune response genes. A parallel blood transcriptional module analysis of the linear model showed type I interferon and innate response genes were more down-5 regulated, while conversely genes involved in B-cell biology were more up-regulated after 6 7 doxycycline treatment. In several other blood transcriptional studies, interferon-inducible genes 8 (both type I and II interferon signaling) and innate immune-related genes are highly expressed in TB patients (65-67) and their expression diminishes to that of healthy individuals after successful 9 10 standard anti-TB treatment (67-70). In addition, B-cell markers increase in expression only at the 11 later phases of treatment during disease resolution (69). Thus, the greater change of these pathways after 14 days of additional doxycycline treatment suggests that doxycycline hasten the 12 normalization of gene expression relative to standard anti-TB treatment. 13

The doxycycline course lasted for two weeks, but the change in expression levels of TBassociated immune response genes persisted for six weeks after doxycycline discontinuation. Similar long-term suppressive effect was also observed on plasma MMP-1, which is often elevated in active TB patients (31). These findings suggest that doxycycline host-directed therapy sustains modulations to the host immune responses.

Adjunctive doxycycline specifically suppresses MMPs and their functional activity in pulmonary TB patients. In particular, MMP-1, -8, -9, -12, and -13, and cleavage of Type I collagen and elastin in the respiratory compartment were down-regulated by doxycycline, while the tissue inhibitor of MMPs, TIMP-1 and -2, remained unchanged. This MMP suppression is likely due to the direct effect of doxycycline (71), since sputum *Mtb* loads were unchanged. Multiple studies

have demonstrated collagenases MMP-1 and -8 and gelatinase MMP-9 to be elevated in respiratory 1 samples of TB patients, and are closely associated with parameters of immunopathology, such as 2 3 cavitation and chest radiograph infiltration (14, 29, 30, 33). Although humans express more than 20 MMPs (72), the luminex bead array can only analyze for 10 MMPs, including EMMPRIN, and 4 so our analysis does not cover all MMPs. Overall, our findings of MMP suppression by 5 6 doxycycline suggest it may be useful in limiting TB immunopathology, and may also reduce the risk of pulmonary impairment after TB (20), as has been proposed for other inflammatory diseases 7 (73, 74). Although PIIINP was listed as primary outcome measure at trial conception, no 8 9 difference was observed between groups. These may be due to the interval before analysis, as PIIINP has been reported to be unstable in serum or EDTA plasma after 3 months of storage (75). 10

11 In serial 18-F fluorodeoxyglucose positron emission tomography-computed tomography (18-F FDG PET-CT) scans of pulmonary TB patients, high cavity volume is strongly associated 12 with poor treatment outcome (76). In murine studies, treatment with another broad spectrum MMP 13 14 inhibitor marimastat, increases the potency of frontline TB drugs isoniazid and rifampicin, and enhances the delivery and/or retention of TB drugs in the infected tissue due to improved vascular 15 integrity (39). Conversely, monotherapy of cipemastat, a selective inhibitor of MMP-1, -7, -8 and 16 17 -13, paradoxically increased cavitation, immunopathology, and mortality in a murine model of 18 cavitary TB (77). Similarly, in the rabbit model of cavitary TB, cipemastat monotherapy also did not prevent cavitation (78). In the current study, adjunctive doxycycline decreased the average 19 volume of pulmonary cavities from 23,694 mm³ at Day 0 to 1,136 mm³ at Day 56, suggesting an 20 21 inhibitory effect on cavitation by MMPs suppression when combined with standard anti-TB 22 treatment. Further investigation of MMP inhibition by doxycycline on TB immunopathology and chronic lung tissue damage are merited. 23

Doxycycline at 100 mg twice daily is the maximum clinical dose and approved by the U.S. 1 Food and Drug Administration (79), and so was selected in our placebo-controlled trial. The dose 2 3 required for MMP inhibition in periodontal disease is 20 mg twice daily (80). Murine studies have shown that doxycycline has high organ penetration and reached higher concentrations in both 4 cellular and necrotic TB lesions compared to plasma (81). Combined treatment with rifampin can 5 6 reduce the levels of doxycycline by approximately 67% in plasma, while clearance of doxycycline was increased approximately 2-fold in patients receiving concurrent rifampin (82). However, the 7 8 interaction of doxycycline with standard anti-TB treatment was not evaluated in this study, and 9 the pharmacokinetics of doxycycline should be considered in future trials. Regardless, adjunctive doxycycline with standard anti-TB treatment in pulmonary TB patients is safe from our initial 10 analyses and the safety profile is consistent with recent clinical trials examining doxycycline 11 therapy in other diseases (83, 84). 12

Our study has limitations, including the sample size of 30 pulmonary TB patients and the 13 14 short doxycycline treatment regimen of 2 weeks. Sputum *Mtb* colony forming units (cfu) and chest X-ray (CXR) score remained the same in both arms, although a higher proportion of patients in 15 the doxycycline arm had resolved pulmonary cavities, this did not reach statistical significance, 16 17 whereas analysis of cavity volume did differ. PET-CT would be more sensitive in detecting 18 changes in cavity size and lung inflammation than CXR analysis used in this study. However, due 19 to concerns of substantial radiation exposure by repeated scans and its high operating costs, PET-CT was not used in our study. A larger sample size to sufficiently power future Phase 3 clinical 20 21 trials evaluating the effect of doxycycline on TB immunopathology is needed, which could 22 incorporate weekly collection of sputum for TB cultures to document time to culture conversion.

Lung function tests, pulmonary cavitation, time to conversion of sputum culture, pharmacokinetics
 studies, and adverse drug effects should be considered as outcome measures.

3 The duration of intervention was based on a prospective study showing the rapid decrease 4 of collagenases MMP-1, -3, and -8 levels after 2 weeks of anti-TB treatment (33). Given the current data that doxycycline is safe and suppressed biological markers of tissue destruction, a 5 longer treatment duration in a larger cohort could be considered, similar to other clinical trials, 6 7 which administered doxycycline for at least 4 weeks (41-43). Doxycycline, the only U.S. FDA licensed drug for MMP inhibition, is routinely used as a broad-spectrum antibiotic, and may have 8 off-target effects other than MMPs. Indeed, doxycycline was shown to have comprehensive 9 10 immunomodulation effects on cytokines and chemokines levels and production (85, 86), and may also influence the composition of the gastrointestinal microbiota (87). 11

12 In summary, adjunctive doxycycline with standard anti-TB treatment is associated with 13 accelerated normalization of the increased type I/II interferon response and innate immune 14 response genes in TB, and up-regulation of suppressed B-cell markers. Doxycycline specifically suppresses systemic MMP-1 and respiratory MMP-1, -8 and -9, inhibits matrix destruction in 15 16 respiratory samples of pulmonary TB patients and reduces pulmonary cavity volume. Adjunctive 17 doxycycline is well-tolerated in TB patients on standard anti-TB treatment. Overall, this study is a stepping stone for larger studies to further evaluate and validate the benefits of adjunctive 18 doxycycline treatment for TB patients. Doxycycline may prove to be a cheap and widely available 19 20 host-directed therapy targeting TB-associated tissue destruction and the associated dysregulated 21 inflammatory immune response.

1 Methods

2 Study design and participants

3 This was a randomized, double-blind, placebo-controlled trial of doxycycline as an adjunct to standard anti-TB treatment in pulmonary TB patients at the National University Hospital (NUH) 4 and the Tuberculosis Control Unit (TBCU), Singapore. Patients were eligible if they were aged 5 6 21-70 years old, have confirmed pulmonary TB with positive acid-fast bacilli smear and/or positive GeneXpert and/or culture results, have a chest radiograph demonstrating pulmonary 7 8 involvement, and were within 7 days of initiating anti-TB treatment. Patients with HIV co-9 infection, previous pulmonary TB, and severe pre-existing lung diseases were excluded. Other 10 exclusion criteria included pregnancy or breast feeding; allergies to tetracyclines; on retinoic acid, 11 neuromuscular blocking agents and pimozide treatment; autoimmune disease and/or on systemic 12 immunosuppressants; hemoglobin lower than 8 g/dl; creatinine 2 times upper limit of normal 13 (ULN); ALT above 3 times ULN; severe depression, schizophrenia or mania. Healthy volunteers 14 aged 21–70 years and in general good health were enrolled at Investigational Medicine Unit, NUH. The complete list of eligibility criteria can be found in the study protocol (available at 15 https://scholarbank.nus.edu.sg/handle/10635/171211). In total, 30 pulmonary TB patients and 10 16 17 healthy volunteers were recruited from 2015 to 2017. Due to unintentional administrative oversight, the trial was registered in ClinicalTrials.gov (NCT02774993) after the full ethical 18 approval, Singapore Health Science Authority clinical trial certificate (CTC1400221) and study 19 start date. Monitoring of the clinical trial was performed by the Singapore Clinical Research 20 Institute (SCRI). 21

22

23 Study procedures

TB patients were randomly assigned (1:1) using www.randomisation.com to receive daily self-administered doxycycline 100 mg bd or matching placebo (Beacons Pharmaceuticals) for 14 days (Figure 1). Participants, clinicians, and the study team were masked to treatment allocations during the conduct of the trial. TB patients were prescribed standard anti-TB treatment, in conjunction with the study drug. Healthy volunteers were given 14 days of doxycycline and were not randomized.

7 Participants were followed up at Day 14 and 56 ± 2 days for safety monitoring and sample 8 collection. Criteria for cessation of study intervention include serious adverse events related to the study drug, participant withdrawal of consent, and other reasons specified in the study protocol. 9 10 A pill count was performed at the end of study intervention to determine adherence. Participants were excluded from downstream assessment if they missed 4 doses of the study drug. Induced 11 sputum was collected from TB patients at Day 0 and 14, while chest radiograph and whole blood 12 were taken at Day 0, 14, and 56. For healthy volunteers, blood collection was performed at Day 13 14 0, 14, and 56. All samples were sent for immediate processing in the BSL-3 laboratory at National University of Singapore (NUS). 15

16

17 Samples collection and processing

Sputum induction was performed in designated collection rooms, where TB patients were nebulized with 5% saline in 5-minute cycles, up to 20 minutes as tolerated. Sputum samples were liquefied as previously described (29) and sterile filtered through 0.22 μm Durapore PVDF membrane (Merck Millipore) to remove *Mtb* (88).

Whole blood was collected separately into Tempus[™] Blood RNA tubes (Applied 1 Biosystems) for RNA-sequencing, and 50 mL tube containing EDTA (1st BASE) for plasma 2 processing, as well as neutrophils and monocytes isolation. Plasma obtained after blood 3 centrifugation was sterile filtered through 0.22 µm Durapore PVDF membrane. Neutrophils and 4 monocytes were respectively isolated from blood samples using CD15- and CD14-antibody 5 6 conjugated pluriBeads (pluriSelect), following manufacturer's instructions. Cell viability was > 99% by trypan blue assay, and neutrophil and monocyte purities were > 95% and > 80% by flow 7 8 cytometry respectively.

9

10 **Outcome measures**

11 The primary outcome measure was change of PIIINP in TB patients. Other outcome 12 measures include change of MMPs and TIMPs in plasma and sputum samples, change of 13 collagenase and elastase activities in sputum samples, change of *Mtb*-induced MMP secretion from 14 isolated neutrophils and monocytes, change of whole blood transcriptome, change of *Mtb* cfu in 15 sputum samples

16

17 Chest radiograph analysis and *Mtb* cfu measurement

Chest radiographs of TB patients were scored for extent of pulmonary consolidation as described previously (29) by 2 specialists blinded to the intervention (CWMO and PTE) and the absence or presence of cavitation by 2 out of 3 specialists (CWMO, PTE and FSWT). Chest-X-ray infiltration (CXR) was scored on a scale of 0 - 10 depending on the number of segments involved, on a modified scoring system developed by Lawson *et al* (29, 89). Pulmonary cavity volume was estimated by measuring its radius in ImageJ (90), and calculated as $V = \frac{4}{3}\pi r^3$. Liquefied sputum was serially diluted and plated for cfu enumeration on Middlebrook 7H11 agar (BD Biosciences) supplemented with OADC growth enrichment, polymyxin B, carbenicillin, amphotericin B and trimethoprim (Sigma-Aldrich).

5

6 Whole blood RNA-sequencing

7 Blood samples collected in TempusTM Blood RNA tubes were processed following the manufacturer's protocol to obtain the RNA pellet in Step 8 (Thermo Fisher Scientific). The pellet was 8 9 re-suspended in 1 mL TRIzol (Thermo Fisher Scientific), and total RNA was extracted by acid guanidinium thiocyanate-phenol-chloroform extraction followed by Qiagen RNeasy Micro clean-up 10 procedure. All RNAs were analyzed on Agilent Bioanalyzer for quality assessment. Only 15 TB 11 12 patients (8 placebo and 7 doxycycline) and 6 healthy volunteers had a complete set of samples (Day 0, 14 and 56) that qualified for RNA-sequencing, with RNA Integrity Number (RIN) ranging from 6.4 to 13 9.2 and median RIN of 8. cDNA libraries were prepared as described previously (91) using SMARTSeq 14 15 v2 protocol (54). The length distribution of the cDNA libraries was monitored using DNA High Sensitivity Reagent Kit on the Perkin Elmer Labchip GX system. All samples were subjected to an 16 indexed paired-end sequencing run of 2x151 cycles on an Illumina HiSeq 4000 (69 samples in 4 lanes). 17

Paired-end sequence reads were quantified to transcript abundance using Kallisto (92) with bias correction, and 50 bootstrap samples. Reads were mapped to ENSEMBL release 95. On average, the percentage of aligned reads is 89.3%. The transcript abundance was then summarized to gene level using Sleuth (93).

1 Differential Gene Expression (DEG) analysis

2	Raw counts from RNA-sequencing were processed in Bioconductor package EdgeR (46),
3	variance was estimated, and size factor normalized using Trimmed Mean of M-values (TMM).
4	Genes with minimum 2 reads at minimum 50% samples were included in the downstream analyses.
5	All fit models included a term to model individual variation. For the identification of DEGs over
6	time (Day 14 vs. Day 0), a paired model was used, whereas for the comparison of treatment effect
7	between placebo and doxycycline, a nested design was applied ((Doxy_Day14-Doxy_Day0)-
8	(Placebo_Day14-Placebo_Day0)). Genes with a false discovery rate (FDR)-corrected <i>p</i> -value <
9	0.05 were identified as differentially expressed, resulting from a likelihood ratio test using a
10	negative binomial generalized linear model fit.

11

12 Transcript-to-transcript co-expression analysis

13 Transcript-to-transcript co-expression analysis were done on filtered TMM normalised 14 genes using GraphiaPro (51) (Pearson r = 0.8, Markov Clustering Algorithm MCL = 1.7) and 15 CEMITool (50) (min_ngen = 30, diss_thresh = 0.8, $r^2 = 0.8247$, beta = 3).

16

17 Gene ontology and pathway enrichment analysis

Gene ontology and pathway enrichment analysis were done using Camera (53) or Ensemble of Gene Set Enrichment Analyses (EGSEA) (52). Additionally, blood transcriptional modules (BTMs) (54) were used as gene sets. BTM activity was calculated using the BTM package (Version 1.015) in Python using the normalized counts as input.

1 *ex vivo* culture and stimulation

Mth H37Ry labo

Mtb H37Rv laboratory strain was first cultured in supplemented Middlebrook 7H9 medium
(BD Biosciences) and used at mid-logarithmic growth (optical density of 0.60) for infection of the
isolated neutrophils and monocytes as described (14). Neutrophils were infected at a multiplicity
of infection (MOI) of 10 for 4 hours, while monocytes were infected at MOI of 1 for 24 hours.
Culture supernatants were sterile filtered through 0.22 µm Durapore PVDF membrane to remove *Mtb*.

8

9 ELISAs for TIMP-1/2, PIIINP, and desmosine

10 TIMP-1 and -2 concentrations were measured using Duoset ELISA Development System 11 (R&D Systems), with minimum detection limit of 31.2 pg/mL for both; PIIINP using human PIIINP ELISA kit (Cloud-Clone Corp.), with 25.9 pg/mL detection limit; desmosine using human 12 desmosine ELISA kit (Cusabio), with 39.0 pg/mL detection limit. All ELISAs were performed 13 according to the manufacturer's instructions. Plasma samples were diluted to 1:200 for TIMP-1 14 and -2, 1:100 for PIIINP, and 1:300 for desmosine. Sputum samples were diluted to 1:500 for 15 TIMP-1, 1:5 for TIMP-2, 1:150 for PIIINP, and 1:100 for desmosine. Results from sputum 16 samples were normalized by their total protein concentrations that were qualified by Bradford 17 assay (Bio-Rad). 18

19

20 Luminex array for MMPs

EMMPRIN, MMP-1, -2, -3, -7, -8, -9, -10, -12, and -13 concentrations were analyzed by the Magnetic Luminex Performance Assay (R&D Systems) on the Bio-Plex analyzer (Bio-Rad), according to the manufacturer's protocol. The minimum detection limit for the 10 analytes were 5.6, 1.1, 12.6, 2.9, 6.6, 7.8, 5.7, 3.2, 0.7 and 63.5 pg/mL, respectively. Culture supernatants from *ex vivo* neutrophils cultures were diluted to 1:50 for both MMP-8 and -9, while supernatants from monocytes cultures were assayed at neat for all analytes. Plasma and sputum samples were diluted to 1:5 for all analytes, except for plasma MMP-2 (1:50), and sputum MMP-8 and -9 (1:200 for both). Results from sputum samples were normalized by their total protein concentrations.

7

8 DQ collagen and elastin degradation assays

9 Type I collagen and elastin degradation by sputum samples were respectively assessed at 10 1:8 dilution using EnzChek[®] Gelatinase/Collagenase and EnzChek[®] Elastase assay kits (Molecular 11 Probes), as described previously (14). Samples were activated with 2 mM of p-12 aminophenylmercuric acetate (APMA) for 1 hour at 37°C, before mixing with the DQ collagen 13 (10 μ g) or elastin (5 μ g). Matrix degradation activity was measured after 24 hours with a 14 fluorescence plate reader (BioTek Instruments). Results were normalized by the total protein 15 concentration.

16

17 Statistics

18 Results of the trial were reported in accordance with the CONSORT guidelines. Data were 19 analyzed using GraphPad Prism (version 7, GraphPad Software). Multiple intervention 20 experiments were compared using two-way ANOVA with Sidak's multiple comparisons, while 21 continuous variables between 2 sets of data were assessed using two-tailed Mann-Whitney *U* test.

1	Categorical data were analyzed using Fisher's exact test. Data are expressed as mean \pm s.e.m.
2	unless stated otherwise. Adjusted p -value < 0.05 was considered statistically significant.
3	
4	Data and materials availability
5	All the notebooks used for the RNA-sequencing analysis are available at
6	https://github.com/afvallejo/Doxycycline-as-host-directed-therapy-in-pulmonary-tuberculosis.
7	The raw data was deposited at the European Nucleotide Archive (ENA) under the accession
8	number PRJEB38126.
9	
10	Study approval
11	The Domain Specific Review Board from National Healthcare Group Singapore approved
12	this study (Reference: 2014/0222) and written informed consent or a thumb-print was obtained
13	from all participants prior to inclusion in the study. Two people on a data safety and monitoring
14	board provided oversight during the study.
15	
16	Author contributions
17	C.W.M.O., J.S.F. and P.T.E. conceived the clinical trial. Y.D., F.S.W.T., A.D.Y.W.,
18	S.H.G., H.W.S., C.B.E.C., Y.T.W. and C.W.M.O. carried out the trial. J.S.F., N.I.P., P.A.T.,
19	P.T.E. and C.W.M.O. analyzed the clinical trial. J.L., A.T. and A.S. performed the RNA-
20	sequencing. Q.H.M., Y.W., J.M.H., C.B. and H.R.L. performed the biological assays. Q.H.M.,
21	P.T.E., T.Z.T., A.F.V., M.E.P., A.S., J.S.F. and C.W.M.O. analyzed the RNA-sequencing data and

biological data. Q.H.M., P.T.E. and C.W.M.O. wrote the first draft of the paper which was
reviewed and revised by all authors.

3

4 Acknowledgments

5 We are grateful to the subjects who participated in this study. We thank the operations 6 team of NUS BSL-3 core facility for the logistical support of the study. We express gratitude to 7 Associate Professors Sophia Archuleta and David Lye as members of the data safety and 8 monitoring board, and Singapore Clinical Research Institute (SCRI) for study monitoring. We 9 thank Duan Kaibo for initial analysis of the RNA-sequencing data. We acknowledge the use of 10 High-Performance Computing (HPC) Platform and thank Elena Vataga (Computational Modelling 11 Group, University of Southampton) for assistance.

References

2	1.	WHO. Global Tuberculosis Report 2019. 2019.
3	2.	van Kampen SC, et al. International research and guidelines on post-tuberculosis chronic lung disorders: a
4		systematic scoping review. BMJ Glob Health. 2018;3(4):e000745.
5	3.	Romanowski K, et al. Long-term all-cause mortality in people treated for tuberculosis: a systematic review
6		and meta-analysis. Lancet Infect Dis. 2019;19(10):1129-37.
7	4.	Hawn TR, et al. Host-directed therapeutics for tuberculosis: can we harness the host? Microbiol Mol Biol
8		<i>Rev.</i> 2013;77(4):608-27.
9	5.	Wallis RS, et al. Tuberculosisadvances in development of new drugs, treatment regimens, host-directed
10		therapies, and biomarkers. Lancet Infect Dis. 2016;16(4):e34-46.
11	6.	Wallis RS, and Hafner R. Advancing host-directed therapy for tuberculosis. Nat Rev Immunol.
12		2015;15(4):255-63.
13	7.	Kaufmann SH, et al. Progress in tuberculosis vaccine development and host-directed therapiesa state of
14		the art review. Lancet Respir Med. 2014;2(4):301-20.
15	8.	Tiberi S, et al. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and
16		host-directed therapies. Lancet Infect Dis. 2018;18(7):e183-e98.
17	9.	Phelan JJ, et al. Modulating Iron for Metabolic Support of TB Host Defense. Front Immunol. 2018;9:2296.
18	10.	Ong CW, et al. Tuberculosis, pulmonary cavitation, and matrix metalloproteinases. Am J Respir Crit Care
19		Med. 2014;190(1):9-18.
20	11.	Fatima S, et al. Mycobacterium tuberculosis programs mesenchymal stem cells to establish dormancy and
21		persistence. J Clin Invest. 2020;130(2):655-61.
22	12.	Khader SA, et al. Targeting innate immunity for tuberculosis vaccination. J Clin Invest. 2019;129(9):3482-
23		91.
24	13.	Elkington PT, and Friedland JS. Permutations of time and place in tuberculosis. Lancet Infect Dis.
25		2015;15(11):1357-60.
26	14.	Ong CW, et al. Neutrophil-Derived MMP-8 Drives AMPK-Dependent Matrix Destruction in Human
27		Pulmonary Tuberculosis. PLoS Pathog. 2015;11(5):e1004917.

1	15.	Urbanowski ME, et al. Cavitary tuberculosis: the gateway of disease transmission. Lancet Infect Dis.
2		2020;20(6):e117-e28.
3	16.	Kaplan G, et al. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed
4		immunity. Infect Immun. 2003;71(12):7099-108.
5	17.	Elkington PT, et al. Tuberculosis immunopathology: the neglected role of extracellular matrix destruction.
6		<i>Sci Transl Med.</i> 2011;3(71):71ps6.
7	18.	Rohlwink UK, et al. Matrix Metalloproteinases in Pulmonary and Central Nervous System Tuberculosis-A
8		Review. Int J Mol Sci. 2019;20(6).
9	19.	Pasipanodya JG, et al. Pulmonary impairment after tuberculosis and its contribution to TB burden. BMC
10		Public Health. 2010;10:259.
11	20.	Ravimohan S, et al. Tuberculosis and lung damage: from epidemiology to pathophysiology. Eur Respir
12		<i>Rev.</i> 2018;27(147).
13	21.	Meghji J, et al. Patient outcomes associated with post-tuberculosis lung damage in Malawi: a prospective
14		cohort study. Thorax. 2020;75(3):269-78.
15	22.	Amaral AF, et al. Tuberculosis associates with both airflow obstruction and low lung function: BOLD
16		results. Eur Respir J. 2015;46(4):1104-12.
17	23.	Byrne AL, et al. Tuberculosis and chronic respiratory disease: a systematic review. Int J Infect Dis.
18		2015;32:138-46.
19	24.	Menezes AM, et al. Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin
20		America. Eur Respir J. 2007;30(6):1180-5.
21	25.	Sabir N, et al. Matrix metalloproteinases: Expression, regulation and role in the immunopathology of
22		tuberculosis. Cell Prolif. 2019;52(4):e12649.
23	26.	Kubler A, et al. Mycobacterium tuberculosis dysregulates MMP/TIMP balance to drive rapid cavitation and
24		unrestrained bacterial proliferation. J Pathol. 2015;235(3):431-44.
25	27.	Kessenbrock K, et al. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell.
26		2010;141(1):52-67.
27	28.	Parks WC, et al. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev

28 *Immunol.* 2004;4(8):617-29.

1	29.	Walker NF, et al. Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases.
2		Am J Respir Crit Care Med. 2012;185(9):989-97.
3	30.	Elkington P, et al. MMP-1 drives immunopathology in human tuberculosis and transgenic mice. J Clin
4		Invest. 2011;121(5):1827-33.
5	31.	Walker NF, et al. Matrix Degradation in Human Immunodeficiency Virus Type 1-Associated Tuberculosis
6		and Tuberculosis Immune Reconstitution Inflammatory Syndrome: A Prospective Observational Study.
7		Clin Infect Dis. 2017;65(1):121-32.
8	32.	Seddon J, et al. Procollagen III N-terminal propeptide and desmosine are released by matrix destruction in
9		pulmonary tuberculosis. J Infect Dis. 2013;208(10):1571-9.
10	33.	Ugarte-Gil CA, et al. Induced sputum MMP-1, -3 & -8 concentrations during treatment of tuberculosis.
11		PLoS One. 2013;8(4):e61333.
12	34.	Elkington PT, et al. Mycobacterium tuberculosis, but not vaccine BCG, specifically upregulates matrix
13		metalloproteinase-1. Am J Respir Crit Care Med. 2005;172(12):1596-604.
14	35.	Elkington PT, et al. Synergistic up-regulation of epithelial cell matrix metalloproteinase-9 secretion in
15		tuberculosis. Am J Respir Cell Mol Biol. 2007;37(4):431-7.
16	36.	Ong CWM, et al. Hypoxia increases neutrophil-driven matrix destruction after exposure to Mycobacterium
17		tuberculosis. Sci Rep. 2018;8(1):11475.
18	37.	Ong CW, et al. Complex regulation of neutrophil-derived MMP-9 secretion in central nervous system
19		tuberculosis. J Neuroinflammation. 2017;14(1):31.
20	38.	Parasa VR, et al. Inhibition of Tissue Matrix Metalloproteinases Interferes with Mycobacterium
21		tuberculosis-Induced Granuloma Formation and Reduces Bacterial Load in a Human Lung Tissue Model.
22		Front Microbiol. 2017;8:2370.
23	39.	Xu Y, et al. Matrix metalloproteinase inhibitors enhance the efficacy of frontline drugs against
24		Mycobacterium tuberculosis. PLoS Pathog. 2018;14(4):e1006974.
25	40.	Sang QX, et al. Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment
26		of cardiovascular and neoplastic diseases. Curr Top Med Chem. 2006;6(4):289-316.
27	41.	Gapski R, et al. Systemic MMP inhibition for periodontal wound repair: results of a multi-centre
28		randomized-controlled clinical trial. J Clin Periodontol. 2009;36(2):149-56.

1	42.	Dalvi PS, et al. Effect of doxycycline in patients of moderate to severe chronic obstructive pulmonary
2		disease with stable symptoms. Ann Thorac Med. 2011;6(4):221-6.
3	43.	Bhattacharyya P, et al. Long-term use of doxycycline can improve chronic asthma and possibly
4		remodeling: the result of a pilot observation. J Asthma Allergy. 2012;5:33-7.
5	44.	Lougheed KE, et al. New anti-tuberculosis agents amongst known drugs. Tuberculosis (Edinb).
6		2009;89(5):364-70.
7	45.	Collins L, and Franzblau SG. Microplate alamar blue assay versus BACTEC 460 system for high-
8		throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium.
9		Antimicrob Agents Chemother. 1997;41(5):1004-9.
10	46.	Robinson MD, et al. edgeR: a Bioconductor package for differential expression analysis of digital gene
11		expression data. Bioinformatics. 2010;26(1):139-40.
12	47.	Kanehisa M, and Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res.
13		2000;28(1):27-30.
14	48.	Kanehisa M, et al. New approach for understanding genome variations in KEGG. Nucleic Acids Res.
15		2019;47(D1):D590-D5.
16	49.	Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci.
17		2019;28(11):1947-51.
18	50.	Russo PST, et al. CEMiTool: a Bioconductor package for performing comprehensive modular co-
19		expression analyses. BMC Bioinformatics. 2018;19(1):56.
20	51.	Theocharidis A, et al. Network visualization and analysis of gene expression data using BioLayout
21		Express(3D). Nat Protoc. 2009;4(10):1535-50.
22	52.	Alhamdoosh M, et al. Combining multiple tools outperforms individual methods in gene set enrichment
23		analyses. Bioinformatics. 2017;33(3):414-24.
24	53.	Ritchie ME, et al. limma powers differential expression analyses for RNA-sequencing and microarray
25		studies. Nucleic Acids Res. 2015;43(7):e47.
26	54.	Picelli S, et al. Full-length RNA-seq from single cells using Smart-seq2. Nat Protoc. 2014;9(1):171-81.
27	55.	Ma S, et al. The detection and quantitation of free desmosine and isodesmosine in human urine and their
28		peptide-bound forms in sputum. Proc Natl Acad Sci USA. 2003;100(22):12941-3.

1	56.	Murphy G, and Nagase H. Localizing matrix metalloproteinase activities in the pericellular environment.
2		<i>Febs j.</i> 2011;278(1):2-15.
3	57.	Mithieux SM, and Weiss AS. Elastin. Adv Protein Chem. 2005;70:437-61.
4	58.	Seyer JM, et al. Collagen polymorphism in idiopathic chronic pulmonary fibrosis. J Clin Invest.
5		1976;57(6):1498-507.
6	59.	Cathcart J, et al. Targeting Matrix Metalloproteinases in Cancer: Bringing New Life to Old Ideas. Genes
7		Dis. 2015;2(`1):26-34.
8	60.	Yen YF, et al. Association of Body Mass Index With Tuberculosis Mortality: A Population-Based Follow-
9		Up Study. Medicine (Baltimore). 2016;95(1):e2300.
10	61.	Singhania A, et al. The value of transcriptomics in advancing knowledge of the immune response and
11		diagnosis in tuberculosis. Nat Immunol. 2018;19(11):1159-68.
12	62.	Blankley S, et al. A 380-gene meta-signature of active tuberculosis compared with healthy controls. Eur
13		Respir J. 2016;47(6):1873-6.
14	63.	Zak DE, et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet.
15		2016;387(10035):2312-22.
16	64.	Sweeney TE, et al. Genome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort
17		analysis. Lancet Respir Med. 2016;4(3):213-24.
18	65.	Scriba TJ, et al. Sequential inflammatory processes define human progression from M. tuberculosis
19		infection to tuberculosis disease. PLoS Pathog. 2017;13(11):e1006687.
20	66.	Bloom CI, et al. Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary
21		sarcoidosis, pneumonias and lung cancers. PLoS One. 2013;8(8):e70630.
22	67.	Berry MP, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human
23		tuberculosis. Nature. 2010;466(7309):973-7.
24	68.	Bloom CI, et al. Detectable changes in the blood transcriptome are present after two weeks of
25		antituberculosis therapy. PLoS One. 2012;7(10):e46191.
26	69.	Cliff JM, et al. Distinct phases of blood gene expression pattern through tuberculosis treatment reflect
27		modulation of the humoral immune response. J Infect Dis. 2013;207(1):18-29.

1	70.	Cliff JM, et al. The human immune response to tuberculosis and its treatment: a view from the blood.
2		Immunol Rev. 2015;264(1):88-102.
3	71.	Hanemaaijer R, et al. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and
4		endothelial cells. Regulation by tumor necrosis factor-alpha and doxycycline. J Biol Chem.
5		1997;272(50):31504-9.
6	72.	Jackson BC, et al. Update of human and mouse matrix metalloproteinase families. Hum Genomics.
7		2010;4(3):194-201.
8	73.	Henehan M, et al. Doxycycline as an anti-inflammatory agent: updates in dermatology. J Eur Acad
9		Dermatol Venereol. 2017;31(11):1800-8.
10	74.	Garrido-Mesa J, et al. Immunomodulatory tetracyclines shape the intestinal inflammatory response
11		inducing mucosal healing and resolution. Br J Pharmacol. 2018;175(23):4353-70.
12	75.	Cavalier E, et al. Critical analytical evaluation of promising markers for sarcopenia. European Geriatric
13		Medicine. 2016;7(3):239-42.
14	76.	Malherbe ST, et al. Quantitative 18F-FDG PET-CT scan characteristics correlate with tuberculosis
15		treatment response. EJNMMI Res. 2020;10(1):8.
16	77.	Ordonez AA, et al. Matrix Metalloproteinase Inhibition in a Murine Model of Cavitary Tuberculosis
17		Paradoxically Worsens Pathology. J Infect Dis. 2019;219(4):633-6.
18	78.	Urbanowski ME, et al. Repetitive Aerosol Exposure Promotes Cavitary Tuberculosis and Enables
19		Screening for Targeted Inhibitors of Extensive Lung Destruction. J Infect Dis. 2018;218(1):53-63.
20	79.	FDA. Drug approval package - Application No.: 050795.
21		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/050795s000_DoryxTOC.cfm. Accessed 23th
22		April 2021.
23	80.	Gapski R, et al. Effect of systemic matrix metalloproteinase inhibition on periodontal wound repair: a proof
24		of concept trial. J Periodontol. 2004;75(3):441-52.
25	81.	Gelhaus HC, et al. Efficacy of post exposure administration of doxycycline in a murine model of
26		inhalational melioidosis. Sci Rep. 2013;3:1146.
27	82.	Colmenero JD, et al. Possible implications of doxycycline-rifampin interaction for treatment of brucellosis.
28		Antimicrob Agents Chemother. 1994;38(12):2798-802.

1	83.	Eliassen KE, et al. Comparison of phenoxymethylpenicillin, amoxicillin, and doxycycline for erythema
2		migrans in general practice. A randomized controlled trial with a 1-year follow-up. Clin Microbiol Infect.
3		2018;24(12):1290-6.
4	84.	Baxter BT, et al. Effect of Doxycycline on Aneurysm Growth Among Patients With Small Infrarenal
5		Abdominal Aortic Aneurysms: A Randomized Clinical Trial. JAMA. 2020;323(20):2029-38.
6	85.	Fredeking TM, et al. Dengue Patients Treated with Doxycycline Showed Lower Mortality Associated to a
7		Reduction in IL-6 and TNF Levels. Recent Pat Antiinfect Drug Discov. 2015;10(1):51-8.
8	86.	Sun J, et al. Tetracyclines downregulate the production of LPS-induced cytokines and chemokines in THP-
9		1 cells via ERK, p38, and nuclear factor-κB signaling pathways. Biochem Biophys Rep. 2015;4:397-404.
10	87.	Elvers KT, et al. Antibiotic-induced changes in the human gut microbiota for the most commonly
11		prescribed antibiotics in primary care in the UK: a systematic review. BMJ Open. 2020;10(9):e035677.
12	88.	Elkington PT, et al. Filter sterilization of highly infectious samples to prevent false negative analysis of
13		matrix metalloproteinase activity. J Immunol Methods. 2006;309(1-2):115-9.
14	89.	Lawson L, et al. Clinical presentation of adults with pulmonary tuberculosis with and without HIV
15		infection in Nigeria. Scand J Infect Dis. 2008;40(1):30-5.
16	90.	Schindelin J, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods.
17		2012;9(7):676-82.
18	91.	Chakarov S, et al. Two distinct interstitial macrophage populations coexist across tissues in specific
19		subtissular niches. Science. 2019;363(6432).
20	92.	Bray NL, et al. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol. 2016;34(5):525-7.
21	93.	Pimentel H, et al. Differential analysis of RNA-seq incorporating quantification uncertainty. Nat Methods.
22		2017;14(7):687-90.
23	94.	Eldridge SM, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ.
24		2016;355:i5239.

Baseline characteristics	Placebo $(n = 15)$	Doxycycline (n = 15)	Total (n = 30)	<i>p</i> -value *
Median age, years (IQR)	49 (42 - 59)	42 (26 - 58)	47.5 (34.8 - 58.3)	0.29
Male : Female^	13:2	11:4	24:6	0.65 #
Diabetes (%)	6 (40%)	3 (20%)	9 (30%)	0.43 #
Mean HbA1c, % ⁺	11.1	11.7	11.3	
Median weight, kg (IQR)	55.4 (41.2 - 73.4)	51.5 (46.7 - 63.2)	54.4 (46.6 - 67.6)	0.42
Median BMI, kg/m ² (IQR)	21.0 (18.5 - 24.6)	20.7 (18.7 – 22.1)	20.9 (18.7 – 23.2)	0.53
Median WBC (IQR)	8.5 (6.3 – 10.4)	7.7 (5.9 – 9.0)	8.3 (6.1 – 9.5)	0.22
Median Hb, g/dL (IQR)	13.9 (12.6 – 14.5)	13.7 (11.8 – 14.7)	13.8 (12.3 – 14.6)	0.47
Median ALT (IQR)	20 (16 – 24)	19 (12 – 24)	19 (13–24)	0.38
Median AST (IQR)	23 (21 – 28)	22 (16 – 25)	23 (19 – 26)	0.50
Median Creatinine (IQR)	66 (57 – 71)	78 (62 - 85)	69 (59 - 82)	0.11
Median AFB smear (IQR)	2 (0 – 3)	2 (1 – 3)	2 (1 – 3)	0.85
Isoniazid mono-resistant Mtb (%)	1 (7%)	1 (7%)	2 (7%)	1.00 #
Median Mtb CFU/ml (IQR)	8,500 (25 - 152,500)	6,125 (0 - 75,000)	8,500 (25 - 106,250)	0.46
Median CXR score (IQR)	3.5 (1.5 – 5.0)	2.5 (2.0 - 4.5)	2.8 (1.9 - 4.6)	0.91
Cavities present (%)	11 (73%)	8 (53%)	19 (63%)	0.45 #
Outcomes	Placebo (n = 13)	Doxycycline (n = 13)	Total (n = 26)	
Clinical outcomes				
Median BMI, Day 14, kg/m ² (IQR)	22.2 (19.4 - 24.5)	20.6 (18.5 - 22.8)	20.8 (19.1 – 23.2)	0.31
Median BMI, Day 28, kg/m ² (IQR)	22.0 (20.1 - 24.3)	21.1 (19.1 – 22.8)	21.3 (20.0 - 23.5)	0.34
Median BMI, Day 56, kg/m ² (IQR)	22.3 (20.2 - 24.2)	21.5 (19.3 – 23.2)	21.9 (20.1 - 23.8)	0.36
Radiological outcomes				
Median CXR score, Day 14 (IQR)	2.5 (1.0 – 4.5)	2.5 (1.3 – 4.5)	2.5 (1.0 – 4.5)	0.87
Median CXR score, Day 56 (IQR)	2.0 (1.0 – 3.0)	1.5 (1.0 – 3.0)	2.0 (1.0 – 3.0)	0.73
Cavities resolved, Day 56 (%)	2 (22%) §	4 (57%) ¶	6 (38%)	0.30 #
Microbiological outcomes				
Median <i>Mtb</i> CFU/ml at Day 14 (IQR)	100 (0 - 1,063)	25 (0 – 125)	38 (0 – 513)	0.32
TB culture positive at 2 nd month (%)	2 (15%)	1 (8%)	3 (12%)	1.00 #

*Clinical variables between placebo and doxycycline arms were compared by Mann-Whitney U

test unless stated otherwise.

#Analysis was performed using Fisher's exact test.

[^]The classification was made by the investigators.

[‡]Mean HbA1c was calculated only among diabetes patients.

§2 patient with pulmonary cavities in the placebo arm withdrew; ¶1 patients with pulmonary

cavities in the doxycycline arm withdrew.

AFB, acid-fast bacilli; ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; CFU, colony forming unit; CXR, chest X-ray; Hb, haemoglobin; HbA1c, glycated haemoglobin; IQR, interquartile range; *Mtb*, *Mycobacterium tuberculosis*; WBC, white blood cell count.




Figure 1. Trial profile (94). The safety analysis included all participants who underwent randomization and received an initial dose of placebo or doxycycline. The downstream assessment included all participants who underwent randomization, took at least 24 out of the 28 doses of placebo or doxycycline, and returned for follow-up at Day 14 and Day 56.




Figure 2. Doxycycline results in faster normalization of type II interferon and innate immune response genes relative to placebo. (A-B) PCA analysis of doxycycline (A) and placebo (B) treated patients at Day 0 (orange) and Day 14 (blue). First two components of PCA are shown and their variances are shown in parenthesis. Doxycycline reduces variation between individuals over the first two weeks of treatment. Only patients with Day 0 and 14 samples are plotted. n = 8placebo, n = 7 doxycycline. (C) Transcript to transcript clustering of 12,977 genes filtered and normalized using Trimmed Mean of M-values (TMM) identified 27 co-expressed clusters (Pearson r = 0.8; Markov Clustering Algorithm, MCL = 1.7; n gene/cluster ≥ 10) over the course of doxycycline treatment. The 15 largest clusters (Supplemental Table 3) are shown in different colors. Lines represent the similarity between transcripts, circles represent individual genes. Two major groupings identify genes preferentially expressed in innate immune response (Granulocytes, Interferon response) and adaptive immune response (T cells). (D-I) Longitudinal analysis of selected genes, IRF1 (D), APOL1 (E), FCGR1A (F), FCGR1B (G), GBP5 (H), and GBP6 (I) from a cluster encoding for type II interferon and innate immune responses. TMM normalized gene expression at Day 0, 14, and 56 of TB patients in placebo (n = 8, green) and doxycycline (Doxy, n = 7, purple) arms, and baseline expression of healthy volunteers (HV, n = 6, blue) are plotted. Box represents 25th and 75th percentile, line is median, with whiskers denoting extremes.




Figure 3. Doxycycline differentially regulates numerous genes in TB pathway relative to placebo. Comparison of gene expression changes (Day 14 vs. Day 0) between placebo and doxycycline (Doxy) arms for genes in the KEGG Tuberculosis pathway (map05152) (47-49). The pathway was identified by Ensemble of Gene Set Enrichment Analyses (EGSEA) (52) to be significantly regulated by doxycycline treatment (adjusted *p*-value = 0.0047). Gene expression changes (Day 14 vs. Day 0) in the placebo and doxycycline arms are respectively shown on the left and right side of each gene box. Red represents up-regulation and blue represents down-regulation of gene expression.




Figure 4. Doxycycline leads to greater down-regulation of type I interferon responses and extracellular matrix genes, and up-regulation of B cells markers relative to placebo. (A) Gene set enrichment analysis of differentially regulated genes specific to doxycycline treatment ((Doxy_Day14-Doxy_Day0)-(Placebo_Day14-Placebo_Day0)). Blood transcriptional modules (54) were used as gene sets. The top 15 enriched gene sets are shown. Dotted line marks adjusted *p*-value = 0.05. Red represents up-regulation and blue represents down-regulation of gene sets. (**B-D**) Longitudinal analysis of type I interferon response gene set (M127) (**B**), extracellular matrix gene set (M2.0) (**C**), and *MMP9* (**D**) at Day 0 and 14 of placebo (n = 8, green) and doxycycline (n = 7, purple) arms. Median expression levels of genes in the gene sets are plotted, while TMM normalized gene expressions are shown for *MMP9*. Box represents 25th and 75th percentile, line is median, with whiskers denoting extremes. **Adjusted *p*-value < 0.01.




Figure 5. Plasma MMP-1 is suppressed by doxycycline but TIMP-1 and -2 are not affected. (A-D) Longitudinal analysis of plasma MMP-1 (A), MMP-8 (B), TIMP-1 (C), and TIMP-2 (D) concentrations at Day 0, 14, and 56 of placebo (n = 12, green) and doxycycline (Doxy, n = 13, purple) arms. Protein concentrations of each subject were normalized to their Day 0 values. Analysis by 2-way ANOVA with Sidak's multiple comparisons. *Adjusted *p*-value < 0.05. Bars represent mean \pm s.e.m.




Figure 6. Sputum MMPs and extracellular matrix degradation activity in TB patients treated with doxycycline are suppressed with a concurrent decrease in cavity volume. (A-G) Longitudinal analysis of sputum MMP-1 (A), MMP-8 (B), MMP-9 (C), TIMP-1 (D), TIMP-2 (E), Type I collagenase activity (F), and elastase activity (G) at Day 0 and 14 of placebo (green) and doxycycline (Doxy, purple) arms. Protein concentrations, as well as functional activity, for each subject were normalized to their Day 0 values. n = 13 placebo and n = 13 doxycycline for MMPs; n = 10 placebo and n = 12 doxycycline for TIMPs; n = 12 placebo and n = 9 doxycycline for functional activity. (H) Longitudinal analysis of cavity volume in patients with pulmonary cavities at Day 0 and 56. n = 9 placebo (green) and n = 7 doxycycline (Doxy, purple). Analysis by 2-way ANOVA with Sidak's multiple comparisons. *Adjusted *p*-value < 0.05. Bars represent mean \pm s.e.m.